November 2020 Vol 11, No 11
With high recurrence and mortality rates, ovarian cancer often has a devastating impact on patients and their loved ones.
The National Accreditation Program for Breast Centers (NAPBC)/American College of Surgeons is dedicated to promoting improved treatment outcomes for breast disease.
Pamela Cloys, MSN, ANP-C, Jason Morrow, RN, BSN, OCN, Noreen Denham, RN, OCN, Regina Franco, MSN, ANP-C, Jeff Giguere, MD, Armand DeSollar, BS, Tanner Huyck
The “Moving On” Oncology Rehabilitation program is a free 12-week exercise program for cancer survivors located at the Prisma Health Cancer Institute Center for Integrative Oncology & Survivorship.
Jessica MacIntyre, APRN, NP-C, AOCNP, Sophie Torrents, MHA, Nancy Farfan, BSN, RN, Aixa Figueroa, Gilbert Pebanco, RN
Sylvester Comprehensive Cancer Center (SCCC) at the University of Miami is an academic medical center in Miami, FL.
Sylvester Comprehensive Cancer Center (SCCC) at the University of Miami is 1 of only 2 cancer centers that have been recognized by the National Cancer Institute in Florida.
Oncology nursing and patient navigation are vital components of optimal cancer care planning, coordination, and delivery within multidisciplinary teams (MDTs).
Early-stage and hormone receptor–positive breast cancers may need additional genomic testing to determine which patients need chemotherapy in addition to endocrine therapy.
Katherine B. Carlson, PhD, Kimberly Lowe, PhD, Basia Bachmann, Benoit Cadieux, PhD, Darcy R. Flora, PhD, David C. Fuehrer, Guy Boike, MD
Cancer patients with bone metastasis or multiple myeloma (MM) are at increased risk for painful and irreversible bone complications known as skeletal- related events (SREs), which include bone fractures, spinal cord compression, and radiation or surgery to the bone.
As a member of the Cancer Care Committee at a community hospital, the thoracic oncology nurse navigator (ONN) recognized the need for a quality study investigating the process for cancer patients receiving PEG tube placement.
The ACS received grant funding from the Merck Foundation to explore navigator network development, implementation, and sustainability.
A professional steering committee for Great Lakes Health Hospital System identified the need to coordinate and integrate an organized oncology service line and attain Commission on Cancer accreditation.
The first cases of COVID-19 in the United States were reported in early January 2020 and began rapidly increasing in March 2020.
Oncology nurse navigators and administrative staff reported spending more than half their daily shifts in some way managing incoming calls and the backlog of voicemails.
One recent study revealed that lung cancer was the most common cancer among those uninsured.
This year, there are no accepted abstracts within this research category.
Paolo Ghia, MD, Andrzej Pluta, MD, Malgorzata Wach, MD, Daniel Lysak, MD, Tomas Kozak, MD, Martin Simkovic, MD, Polina Kaplan, MD, Iryna Kraychok, MD, Arpad Illes, MD, Javier de la Serna, MD, Sean Dolan, MD, Philip Campbell, MD, Gerardo Musuraca, MD, Abraham Jacob, MD, Eric J. Avery, MD, Jae Hoon Lee, MD, Denise Wang, Priti Patel, MD, Wojciech Jurczak, MD
Acalabrutinib is a next-generation, highly selective, covalent Bruton tyrosine kinase inhibitor approved for patients with CLL, including those with R/R CLL.
Caroline Robert, MD, PhD, Jean-Jacques Grob, Daniil Stroyakovskiy, Boguslawa Karaszewska, Axel Hauschild, MD, Evgeny Levchenko, Vanna Chiarion Sileni, MD, Jacob Schachter, MD, Claus Garbe, Igor Bondarenko, Paul Nathan, Antoni Ribas, Michael A. Davies, Keith Flaherty, Paul Burgess, Monique Tan, Eduard Gasal, MD, Dirk Schadendorf, MD, Georgina V. Long, MD, PhD
Two large phase 3 studies (COMBI-d [NCT01584648] and COMBI-v [NCT01597908]) evaluated the efficacy and safety of oral dabrafenib 150 mg twice daily plus trametinib 2 mg once daily (D+T) as first-line therapy in patients (pts) with BRAF V600E- or V600K-mutant unresectable or metastatic cutaneous melanoma.
Krysten Soldan, RN, Carolyn Johns, NP, Matthew H. Taylor, MD, Kathryn Gillis, PharmD, Robert Orlowski, MD, Min Ren, Vicky Makker
Lenvatinib plus pembrolizumab demonstrated promising antitumor activity in endometrial carcinoma (EC) in a phase 1b/2 clinical trial (Study 111/KEYNOTE-146).
Tina DeNofrio, RN, BSN, OCN, Stuart N. Atkinson, MB, ChB, Deborah M. Boldt-Houle, PhD, Julia Vandross, NP-BC, BSN, MSN
Luteinizing hormone-releasing hormone (LHRH) agonists are the most frequently used androgen deprivation therapy (ADT) for prostate cancer (PCa).
Dena Schulman-Green, PhD, Emily Cherlin, PhD, MSW, Renee Capasso, BS, Sarah S. Mougalian, MD, Shiyi Wang, MD, PhD, Cary P. Gross, MD, Preeti S. Bajaj, PhD, Katherine Eakle, PharmD, Sharmi Patel, PharmD, Kerin Adelson, MD
Clinical pathways have increasingly been incorporated into cancer care, aiming to encourage high-quality, evidence-based care while minimizing costs; however, clinical pathways infrequently incorporate patient and family perspectives, limiting patient-centeredness and value for shared decision-making.
Jillian Settlemire, RN, Edythe M. Greenberg, PhD, RN, FNP-BC, Indu Lal, MD, Carlos Amaya-Chanaga, MD, Jan A. Burger, MD, PhD, Steven Coutre, MD
Ibrutinib is the only once-daily Bruton tyrosine kinase inhibitor that has shown significant progression-free survival (PFS) and overall survival (OS) benefits in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) across multiple randomized phase 3 studies.
Laura Beaupre, RN, BSN, OCN, CN-BN, Kathleen Sevedge, RN, MA, AOCN, Angela Miller, RN, BSN, OCN, MEd, Alyssa Pauls, RN, BSN, OCN, Jane Zubia, RN, OCN, CN-BN, Raizalie Roman, RN, BSN, OCN, Maritza Chicas, RN, BSN, OCN, Cynthia Smith, RN, BSN, OCN, MA, Tracy Walczer, RN, BSN, OCN, Jeanne Kenna, RN, OCN, CRNI, Paul Torreson, Eileen Steirer
Oncology nurse navigators and multidisciplinary models of care have been shown to improve outcomes for patients with cancer.
Kathryn A. Pratt, BSN, RN, OCN, CBCN, Sayoni Lahiri, MS, CGC, Sara Pirzadeh-Miller, MS, CGC, Parker Read, MS, CGC
The UT Southwestern Cancer Genetics Program implemented a genetic patient navigator (GPN) to assess patients’ barriers to care, assist patients in identifying resources to increase compliance, promote healthy lifestyle education, and assist with coordination of cascade testing for at-risk relatives.
Lung cancer has the highest mortality rate of all tumor sites.
Patrick Dineen, MD, MBA, Liana Orduña, BS, Darlene Rastelli, MS, RT, (R) (M), Michelle Flores, BS, Monica Roggemann, BS
Nassau and Suffolk counties on Long Island account for over 1500 breast cancer diagnoses annually.
Carla Strom, MLA, Maria Alejandra Combs, JD, OPN-G, Emily Copus, MSW, OPN-CG, Alexis Daniels, MS, OPN-CG, Kelsey Shore, BA, CCRC, Karen Winkfield, MD, PhD
The use of acuity scales to assess cancer patient needs when undergoing treatment is gaining recognition as a way to optimize caseloads for patient navigators (PNs).
A 21-year-old with carcinoma of the nasopharynx was first evaluated by the Head and Neck Oncology Service at Memorial Sloan Kettering Cancer Center (MSKCC) in April 2020.
The process of screening and/or detection to the actual diagnosis of lung cancer involves multiple specialties and diagnostic testing, which can be quite daunting for an individual and his/her family.
Low enrollment rates for cancer clinical trials have been an ongoing barrier to scientific advances in oncology care.
Catherine Nyongesa, MbChB, FC RAD ONCO, MMED RAD ONC, Anastacia Bosire, MScN Onco, Grace Omulogoli, BSc, HSM, Ronniey Obulemire, MPH, Hayley Freedman, MPH, Erica Krisel, MPH
Kenyatta National Hospital (KNH) is the main public hospital in Kenya delivering comprehensive cancer care and receives patients from throughout the country.
- 1
- 2
Page 1 of 2
Results 1 - 30 of 42
Results 1 - 30 of 42
© 2009-2023 DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512